FOR U.S. HEALTHCARE PROFESSIONALS ONLY
The only migraine medication approved to treat and prevent all in one1,2
More than 64,000 providers have written over 3.4 million prescriptions for Nurtec ODT†
The flexibility to help meet your patients’ needs1
Only Nurtec ODT treats and prevents all in one1,2
Well tolerated for acute and preventive treatment1
Dedicated access, savings, and support resources through Nurtec® OneSource
Requesting samples or other tools is one short form away
†Per IQVIA XPO report, accessed 11/14/22. Rankings included new prescriptions and renewals.
More than 286 million individuals have access to Nurtec ODT across all channels*
With coverage for 96% of commercially insured lives*
Nurtec ODT is a preferred oral CGRP receptor antagonist on the UnitedHealthcare national commercial formulary†
Nurtec ODT is the only oral CGRP receptor antagonist on the Anthem national commercial formulary†
Nurtec ODT is a preferred oral CGRP receptor antagonist on the Aetna national commercial formulary†
Nurtec ODT is a preferred oral CGRP receptor antagonist on the Cigna national commercial formulary†
- item 1
- item 2
- item 3
- item 4
Ellie's migraine story
Stress is a trigger for
my migraine attacks.
I know I can count on
Nurtec ODT to help
relieve pain when
a migraine attack strikes in stressful times.
Ellie W.
Actual Nurtec ODT patient.
Individual results may vary.
Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.
After years on the
battlefield and multiple concussions, migraine attacks followed me home...Nurtec ODT is the only medication that can treat and prevent migraine attacks.
Greg P.
Actual Nurtec ODT patient.
Individual results may vary.
Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.
References: 1. Nurtec ODT. Package insert. Pfizer Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7.